https://www.genengne...d-by-rnai-drug/
Unlike cells elsewhere in the body, the cells that form the inner walls of our arteries become inflamed when transforming growth factor-β (TGF-β) proteins circulate. This observation, made by scientists based at Yale University, suggests that interfering with TGF-β receptors could lessen chronic inflammation in blood vessels, which is believed to cause atherosclerosis. The Yale scientists, in fact, have developed a drug that relies on RNA interference (RNAi) to silence TGF-c receptor genes in endothelial cells—and only endothelial cells. This cell-level selectivity is achieved by packing the RNAi drug into an endothelial-cell-targeting nanoparticle.
https://vasrx.com/about/
Hopefully we can get this kind of therapy asap.
Fear not! It is I - the Glucosamine prophet!
No joke though - GS seems to be able to do just what you ask for:
"IL-10 and TGF-β: Roles in Chondroprotective Effects of Glucosamine in Experimental Osteoarthritis?" (2017)
https://www.research...eoarthritis.pdf
It's a small trial in rats, undergoing treatment to induce inflammation in their joints. Using a moderatly high dose of oral GS, much of the inflammation could be prevented (GlcN = Glucosamine in the diagram):
This of course is only indicative of a potential role in endothelial cells. Luckily there is some epidemiological data in humans available concerning CVD-risk (at a rather low dose) and a rabbit-model for arterial disease, which demonstrated some remarkable results of GS for inflammation and CVD - albeit at a really high dose:
https://www.longecit...e-5#entry879575
I guess at the moment - given the safety and cheap online-prices of GS - it beats waiting a couple more years for the RNAi drug.